Document is current

Article History

Accepted: 30 March 2021

First Online: 27 April 2021

Declarations

:

: W. Benjamin Nowell has received research support from AbbVie, Amgen, Eli Lilly, Pfizer, and PCORI. Peter A. Merkel has been a consultant for AbbVie, AstraZeneca, Boeringher-Ingelheim, Bristol-Myers Squibb, ChemoCentryx, CSL Behring, Forbius, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Jannsen, Kiniksa, Kyverna, Magenta,Novartis, Pfizer, Sparrow, Takeda, and Talaris, has received research support from AbbVie, AstraZeneca, Boeringher-Ingelheim, Bristol-Myers Squibb, ChemoCentryx, Forbius, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, and Sanofi, and has received royalties from UpToDate. Robert N. McBurney was a consultant for EMD Serono (consulting fees have been donated to the Accelerated Cure Project [ACP]), the Chief Research Officer ACP, and the Research Lead for the iConquerMS People-Powered Research Network. The ACP has received grants, collaboration funding, payments for use of assets, or in-kind contributions from the following companies: EMD Serono, Novartis, Sanofi/Genzyme, Biogen, Genentech, AbbVie, Octave Bioscience, GlycoMinds, Pfizer, MedDay, AstraZeneca, Teva, Mallinckrodt, MSDx, Regeneron GeneticsCenter, BC Platforms, and Bristol-Myers Squibb (Celgene). The ACP has also received funding from PCORI, the National MS Society, and the Italian MS Society. Shilpa Venkatachalam has received research support from PCORI. Dianne G. Shaw and Kalen Young have no conflicts of interest that are directly relevant to the content of this article. Angela Dobes and Emily Cerciello have received research support from PCORI and report that neither they nor their employer, the Crohn’s & Colitis Foundation, have any conflicts of interest or relationships with industry. Laura Kolaczkowski was a consultant for EMD Serono and Genentech. Jeffrey R. Curtis has been a consultant for AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Eli Lilly, Janssen, Myriad, Pfizer, Roche, Regeneron, Radius, and UCB, and has received research support from AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Eli Lilly, Janssen, Myriad, Pfizer, Roche, Regeneron, Radius, and UCB. Michael D. Kappelman has been a consultant for Abbvie, Janssen, Pfizer, Lilly, and Takeda, a shareholder for Johnson & Johnson, and has received research support from Pfizer, Takeda, Janssen, Abbvie, Lilly, Genentech, Boehringer Ingelheim, Bristol-Myers Squibb, Celtrion, and Arenapharm.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Conception of the work, design of the work, drafting of the manuscript, and critical revision of the manuscript for important intellectual content were performed by WBN, PAM, RNM, KY, SV, DGS, AD, EC, LK, JRC, and MDK.